Abiopharma

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

10x Genomics - 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Scatec signs landmark PPA in Egypt for 1.95 GW Solar and 3.9 GWh BESS capacity